Health Care Worker Training on Roll Out New TB Diagnostic Test. Prepared by: City Health (J Caldwell) & NHLS (M Bosman & I Noordien)
|
|
- Marylou Carter
- 6 years ago
- Views:
Transcription
1 Health Care Worker Training on Roll Out New TB Diagnostic Test Prepared by: City Health (J Caldwell) & NHLS (M Bosman & I Noordien)
2 Overview Specimen Collection Investigations to request Sorting & registering specimens New Diagnostics o GeneXpert NHLS Reports o Fax Lists o Hard Copies o o Telephonic Ordering Diagnostic tests used by NHLS o Microscopy o Culture o Differential o DST o Hain (LPA)
3 Why are we using GeneXpert now? WHO Recommendation (2010) and NSP WHO Strong Recommendation: The new automated DNA test for TB should be used as the initial diagnostic test in individuals suspected of MDR-TB or HIV/TB (i.e. Most TB suspects in SA) Pillars of SA National Strategic Plan: ( draft) Universal testing for HIV and screening for TB the primary objectives being to ensure that all citizens know their HIV and TB status, and to prevent new HIV and TB infections Health and wellness the primary objective being to ensure access to quality treatment, care and support services for those with HIV and/or TB and to develop programmes to focus on wellness Slide courtesy of Prof Wendy Stevens
4 Advantages and limitations Advantages Decreased turn around time to reduce the diagnostic delay Increased sensitivity and specificity Only detects Mycobacterium tuberculosis complex Can be used in children who can cough (induced sputum) Can be used by non-laboratory staff
5 Disadvantages Disadvantages Cannot be used for monitoring Only detects rifampicin resistance Qualitative result Copyright NHLS 2003 Slide 5
6 Specimen Collection NOTE: Quality of the result is ONLY as good as the quality of the specimen received
7 Sputum Collection Use external sputum booths (where available) to collect specimens - if no booth suggest outside building Make sure no other patients are present Always stand BEHIND the patient EXPLAIN the steps to the patient and make sure the patient understands: o Ask the patient to rinse mouth with water o Advise patient to be careful & direct sputum into container so as not to contaminate outside of container o Give the patient LABELLED container without the lid o If the patient does not cough spontaneously, ask the patient to take several deep breaths and then hold their breath o Seal sputum jar properly after specimen produced
8 Closing sputum container Check contents sputum jar Need at least 5ml sputum per jar Tighten cap of sputum jar to make sure it does not leak Place sputum jar into plastic bag obtainable from the NHLS
9 What investigations to request on TB Suspects ALL TB suspects to have 2 spot sputum specimens taken ONE hour apart Previously requested: o New: direct x2 o Retreatment: direct x2 & x1 culture and DST o HCW s, prisoners, contacts DR-TB patients: direct x2 & x1 culture and DST Now request GeneXpert
10 Extrapulmonary samples Circular H Restriction of Genexpert test requests on specimens other than Sputa and Tracheal Aspirate.pdf Copyright NHLS 2003 Slide 10
11 Sputum Request Form Complete the request forms properly Use (PreHmis) PHC patient stickers on sputum jar and on NHLS request form Fold the request form with the patients details facing outward Insert the sample into the correct sleeve of NHLS specimen bag Insert the form into the other sleeve
12 1. Name facility 2. Patient Details (patient sticker) 3. Tests requested MUST add HIV status under remarks (HIV +ve/hivve/hiv unknown) and write GeneXpert 4. Specimen collection details Copyright NHLS 2003 Slide 12
13 Preparation for dispatch sputum specimens to NHLS The TWO plastic bags must be stapled together at the top (each bag contains 1 specimen & 1 request form) Both specimens (stapled together) must be sent to NHLS together and preferably should be sent to NHLS on the same day If it cannot be sent on the same day, keep refrigerated (if no fridge available keep in a cool dark place)
14 Samples stapled together
15 NHLS Sputum Request Form KMBT pdf Copyright NHLS 2003 Slide 15
16 Sorting and Registering Specimens at NHLS On receipt of sputum samples NHLS sorts & registers each specimen received on database BEFORE dispatching to each section for testing. NOTE each specimen has its own unique registration number - each lab has own code (SGT XXXX or SWO XXXX) Leaking specimens are registered BUT discarded report sent to clinic specimen leaked, please repeat
17 Each specimen receives a unique registration number i.e. SGT Information from sputum request form used to register each specimen according to whether suspect/case & TB history i.e. new/rerx
18 TB Suspects Always 0 months New suspect = SPN0 Retreatment suspect = SPR0 Each specimen receives a unique registration number i.e. SGT Information from sputum request form used to register each specimen according to whether suspect/case & TB history i.e. new/rerx Confirmed Drug Sensitive TB Case Conversion sputum done at 7 weeks or 11 weeks New TB case conversion = SPN2 Retreatment TB case conversion = SPR2 Discharge sputum done at 5 months or 7 months New TB case discharge = SPN5 Retreatment TB case discharge = SPR5 Other Please note if no time stated New = SPUN Retreatment = SPUR If it is NOT indicated if a suspect or a case and/or new or retreatment will be registered as SPU Confirmed Drug Resistant TB Case Monthly sputum sample sent on all drug resistant TB cases (MDR and/or XDR) for smear and culture will be registered as SPMDR
19 What TB diagnostic tests are used by NHLS? Diagnostic Tests Direct (microscopy) Culture (MGIT) Drug Sensitivity Testing Line Probe Assay (Hain) New Diagnostic Tests GeneXpert
20 New Diagnostic Test
21 Why the need for new diagnostics? Need tests to confirm diagnosis in sm- TB & drug resistance much sooner to be able to start treatment sooner Direct not very sensitive Culture takes up to 5 weeks
22 MTB/RIF cartridge and GXP 4
23 GeneXpert Technology Xpert MTB/RIF Assay GX1 GX2 GX4 GX16 GeneXpert Infinity throughput/8 hr day
24
25
26 What is GeneXpert (GXP) The GXP is a platform for the Xpert MTB/Rif cartridge-based fully automated nucleic acid amplification test for TB case detection and rifampicin resistance Designed to extract, amplify and identify targeted 6110 and rpob nucleic acid sequences Note - additional tests cannot be ordered after GXP has been done
27 Which samples get GXP? ALL TB suspects one sputum specimen will have genexpert (includes new; ReRx; MDR contacts; HCWs & prisoners) Only 1 GXP test will be done per patient GeneXpert CANNOT be used for follow-up specimens on patients with confirmed TB on treatment need to follow Palsa Plus i.e. & send either smear or culture for conversion & discharge monitoring
28 What are the benefits of GeneXpert? GeneXpert more sensitive To see AFBs on smear needs 10,000 bacilli per ml GeneXpert only needs 150 bacilli per ml Copyright NHLS 2003 Slide 28
29 What are the benefits of GeneXpert? GXP has specificity of 99.2% Detects 70% sm-ve Useful in the diagnosis of TB in HIV co-infected patients Has an instrument turnaround time of 2 hours results will be back at facility within 24 hours Easy to use
30 How to interpret GeneXpert results & what to do?
31 Copyright NHLS 2003 Slide 31
32 GeneXpert +ve and Rifampicin Sensitive 2 GXP MTBCD Pos Rif S.pdf
33 GeneXpert +ve Rifampicin Sensitive On receipt of GeneXpert result Start TB treatment do NOT wait for sm result When sm result received register as either sm+ve OR sm-ve Follow-up at conversion or discharge as per Palsa Plus for sm+ve or sm-ve
34 Copyright NHLS 2003 Slide 34
35 GeneXpert Positive & Rifampicin Resistant 3 MTBCD Rif R.pdf
36 GeneXpert +ve Rifampicin Resistant On receipt GeneXpert result Recall patient for review by PHC MO MO to prescribe MDR treatment with additional INH When cul & DST received MO to review treatment & STOP INH Register patients in DR-TB register
37 Copyright NHLS 2003 Slide 37
38 Rif inconclusive.pdf
39 GeneXpert +ve Rifampicin Inconclusive On receipt GeneXpert result Start drug sensitive TB treatment do NOT wait for sm, culture & DST result When culture & DST result received as RESISTANT stop DS TB treatment & start DR TB treatment When culture & DST result received as SENSITIVE continue DS TB treatment Register as per sm & cul results Copyright NHLS 2003 Slide 39
40 Copyright NHLS 2003 Slide 40
41 GeneXpert Neg.pdf Please note the HIV status Copyright NHLS 2003 Slide 41
42 GeneXpert Negative If HIV+ve NHLS will use 2 nd specimen to do culture & DST On receipt GeneXpert result - manage HIV+ve and HIV-ve as per Palsa Plus
43 Copyright NHLS 2003 Slide 43
44 GXP unsuccesful.pdf
45 GeneXpert Unsuccessful On receipt GeneXpert result If 2 nd GeneXpert unsuccessful take 3 rd specimen for microscopy, culture & DST
46 GeneXpert Fax List NHLS will send out SEPARATE fax list to clinic with genexpert results GeneXpert results will NOT be included on general fax list
47 printer alignment.pdf Copyright NHLS 2003 Slide 47
48 Hard Copy
49 TB Suspect Register GeneXpert TB Suspect Register.xls Copyright NHLS 2003 Slide 49
50 Registration GeneXpert Results Record GeneXpert result in blue TB patient folder as well as any other results i.e. sm/cul Record GeneXpert result in TB register as well as any other results i.e. sm/cul Record as GX+ve/GX-ve
51 Blue TB Folder Pretreatment 2 months 3 months 5/7 months Culture Resistance Sm Date Sm Result Sm Date Sm Result Sm Date Sm Result Sm Date Sm Result Specimen Date Culture result 3/10/11 GX+ve Yes S DST Done R H Z E S 3/10/11 P+++ Remember follow Palsa Plus MUST have a pretreatment smear result for ALL patients tested Gx +ve ALL patients who are sm+ve pretreatment will need to have smears done at 7/11 weeks & 5/7 months ALL patients who are sm-ve pretreatment will NOT have any further sputums sent will be managed clinically for duration treatment
52 Turn Around Time ( TAT ) NTCP expects the laboratory to adhere to a 24 to 48 hour TAT for sputum microscopy TAT is calculated from the date the specimen is taken until the result is received at the clinic Smears on cultures take longer GeneXpert results will be available in 24 hours
53 Copyright NHLS 2003 Slide 53
54 NHLS Reports Copyright NHLS 2003 Slide 54
55 How does a clinic receive results? Fax lists Hard copy of results sent by post or brought to the clinic by the NHLS courier SMS printers Telephonic report Copyright NHLS 2003 Slide 55
56 GeneXpert Fax list.pdf Copyright NHLS 2003 Slide 56
57 Explanation of GXP Fax List GXTB PCR MTBCD Mycobacterium Tuberculosis Detected MTBCN Mycobacterium Tuberculosis NOT Detected GXRIF Rifampicin RIFS Susceptible RIFR RIFZ Resistant Inconclusive Common LEAK Specimen leaked in transit. Please repeat EMTY OSPEC NSMR Received Empty No specimen received No Smear requested
58 SMS result sms printout.pdf Copyright NHLS 2003 Slide 58
59 Auramine Fax Lists Copyright NHLS 2003 Slide 59
60 Explanation of Fax List Copyright NHLS 2003 Slide 60
61 Ordering stores from NHLS material order form.pdf Copyright NHLS 2003 Slide 61
62 ww.disa Before calling the lab please check: Copyright NHLS 2003 Slide 62
63 In summary.. Submit 2 samples together for each suspect GXP simultaneously detects TB and Rifampicin R or S NHLS uses 2 nd sample for further testing Test ordered now shows GeneXP TB Use ww.disa for result lookup
64 Questions????? Copyright NHLS 2003 Slide 64
65 Other Diagnostic Tests
66 Microscopy Directs Microscopy (smear) Copyright NHLS 2003 Slide 66
67 What is microscopy? Also known as direct Two methods of staining specimens o Ziel-Neelsen o Fluorescent auramine staining Dead bacilli on slide AFBs counted under microscope number bacilli (AFB s) reflect infectivity Useful for monotoring diagnosis of smear +ve TB & identifies most infectious cases Copyright NHLS 2003 Slide 67
68 Quantitative Reporting of Microscopy Copyright NHLS 2003 Slide 68
69 Auramine neg 1 Auramine neg.pdf Copyright NHLS 2003 Slide 69
70 Auramine pos 2 Auramine Pos.pdf Copyright NHLS 2003 Slide 70
71 Cultures Cultures MGIT Copyright NHLS 2003 Slide 71
72 What is culture? Specimen processing Liquid culture medium used MGIT automated non-radiometric system uses fluorometric technology Bacilli detected within 7-35 days Much more sensitive than direct Need to confirm bacilli are MTB therefore need to do differential Copyright NHLS 2003 Slide 72
73 Differential Differential confirms if Mycobacterium TB MPT64 Antigens If no sensitivities requested Copyright NHLS 2003 Slide 73
74 MOTT.pdf
75 pos cul with diff.pdf
76 Drug Susceptibility Testing Susceptibility tests are used to determine susceptibility or resistance of bacillary strain to different TB drugs Three types of susceptibility tests o LPA for first line susceptibility test o Phenotypic susceptibility tests for others o Additional requests MGIT susceptibilty tests referred to Jhb Copyright NHLS 2003 Slide 76
77 TB Sensitivities Copyright NHLS 2003 Slide 77
78 What is Hain (Line Probe Assay) The LPA is a molecular diagnostic tool which utilises mycobacterial DNA to identify MTB. Confirms presence or absence of TB Tests first line sensitivities. Not done directly on smear neg samples. Done directly on smear pos suspects not follow up specimens. Follow up specimens: LPA done from MGIT culture. Copyright NHLS 2003 Slide 78
79 Hain (Line Probe Assay) Copyright NHLS 2003 Slide 79
80 Line Probe Assay
81 Direct +ve, PCR MTB +ve (Rif R INH R) 3 PCR pos Rif R INH R.pdf Copyright NHLS 2003 Slide 81
82 Drug Susceptibility Testing Phenotypic Susceptibility Tests Second Line DST Middlebrooks (7H11) Copyright NHLS 2003 Slide 82
83 conventional cul diff sens.pdf
84 Direct +ve PCR MTB +ve (Rif R INH S) 3 PCR pos Rif R INH S.pdf Rif Mono resistance Copyright NHLS 2003 Slide 84
85 LPA 2 neg.pdf
86 LPA 1 neg.pdf
How best to structure a laboratory network with new technologies
How best to structure a laboratory network with new technologies Cristina Gutierrez, MD, PhD Uniting to scale up TB care in Central Asia 14 and 15 April 2011 Tashkent, Uzbekistan New laboratory diagnostics
More informationWhen good genes go bad
When good genes go bad Dr Kessendri Reddy NHLS Tygerberg Hospital Division of Clinical Microbiology Fakulteit Geneeskunde en Gesondheidswetenskappe Faculty of Medicine and Health Sciences Overview Cases
More informationXpert MTB/RIF Training. Indira Soundiram 2012
Xpert MTB/RIF Training Indira Soundiram 2012 A Better Way to Platform Design GeneXpert Infinity-48 GeneXpert Module GX-I GX-II GX-IV GX-XVI 2 Defining Molecular Diagnostics Any Test Any Time Any Sample
More informationDST for detection of DR TB - roll out of Xpert in South Africa and overview of other technologies: what are the gaps?
DST for detection of DR TB - roll out of Xpert in South Africa and overview of other technologies: what are the gaps? Mark Nicol Division of Medical Microbiology and Institute for Infectious Diseases and
More informationKen Jost, BA, has the following disclosures to make:
Diagnosis of TB Disease: Laboratory Ken Jost, BA May 10, 2017 TB Intensive May 9-12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Ken Jost, BA, has the following disclosures to make: No conflict
More informationPOSITIONING OF TB DX : TIERED SYSTEM, INTEGRATED APPROACH
POSITIONING OF TB DX : TIERED SYSTEM, INTEGRATED APPROACH Akos Somoskövi, M.D., Ph.D. and Giorgio Roscigno, M.D. ANNUAL GLI MEETING, 4 th OCTOBER 2010 MERIEUX FOUNDATION, ANNECY Integrated Laboratory Network
More informationDiagnosis of TB: Laboratory Ken Jost Tuesday April 1, 2014
TB Nurse Case Management San Antonio, Texas April 1 3, 2014 Diagnosis of TB: Laboratory Ken Jost Tuesday April 1, 2014 Ken Jost, BA has the following disclosures to make: No conflict of interests No relevant
More informationHIV Clinicians Society Conference TB/HIV Treatment Cascade
HIV Clinicians Society Conference-2012 TB/HIV Treatment Cascade Dr Judith Mwansa-Kambafwile Wits Reproductive Health & HIV Institute University of Witwatersrand TB/HIV Treatment Cascade Overview TB stats
More informationProgress Report March 2016
Progress Report March 2016 Table of Contents Background to project 3 Assays performed to date 3 Correctional Services 5 Peri-Mining 6 Rif Concordance 7 Training: Laboratory and Clinical 7 Challenges identified
More informationOverview of Mycobacterial Culture, Identification, and Drug Susceptibility Testing
Overview of Mycobacterial Culture, Identification, and Drug Susceptibility Testing 1. Essentials for the Mycobacteriology Laboratory: Promoting Quality Practices 1.1 Overview: Mycobacterial Culture, Identification,
More informationDiagnosing Xpert MTB/RIF negative TB suspects: Impact and cost of an alternative algorithm
Diagnosing Xpert MTB/RIF negative TB suspects: Impact and cost of an alternative algorithm Kathryn Schnippel 1, Gesine Meyer-Rath 1,2, Lawrence Long 1, Wendy Stevens 3,4, Ian Sanne 1,2, and Sydney Rosen
More informationEpidemiology and diagnosis of MDR-TB in children H Simon Schaaf
Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg Children s Hospital (TCH) Definitions
More informationStacy White, PhD May 12, TB for Community Providers. Phoenix, Arizona
Role of the Laboratory in TB Diagnosis Stacy White, PhD May 12, 2015 TB for Community Providers May 12, 2015 Phoenix, Arizona EXCELLENCE EXPERTISE INNOVATION Stacy White, PhD has the following disclosures
More informationDiagnosis of TB: Laboratory Ken Jost Tuesday April 9, 2013
TB Nurse Case Management San Antonio, Texas April 9-11, 2013 Diagnosis of TB: Laboratory Ken Jost Tuesday April 9, 2013 Ken Jost has the following disclosures to make: No conflict of interests No relevant
More informationCDPH - CTCA Joint Guidelines Guideline for Micobacteriology Services In California
CDPH - CTCA Joint Guidelines Guideline for Micobacteriology Services In California These guidelines are intended to be used as an educational aid to help clinicians make informed decisions about patient
More informationNAAT in the Clinical Laboratory and Impact on Infection Control 9 th National Conference on Laboratory Aspects of Tuberculosis APHL
NAAT in the Clinical Laboratory and Impact on Infection Control 9 th National Conference on Laboratory Aspects of Tuberculosis APHL Susan Novak-Weekley, S(M), ASCP, Ph.D., D(ABMM) Director of Microbiology,
More information<<Insert Laboratory Logo if applicable>> LABORATORY MANUAL MYCOBACTERIOLOGY CLINICAL SITE
LABORATORY MANUAL MYCOBACTERIOLOGY CLINICAL SITE Protocol Title: A Phase 3, Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability
More informationXpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it
Xpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it Angela Starks, PhD Chief, Laboratory Branch Division of TB Elimination Matt Bankowski, PhD, MS, D(ABMM), HCLD/CC(ABB)
More informationTB Laboratory for Nurses
TB Laboratory for Nurses Shea Rabley, RN, MN Consultant Mayo Clinic Center for Tuberculosis 2014 MFMER slide-1 Disclosures None 2014 MFMER slide-2 Objectives Participants will be able to: 1. Name 2 safety
More informationTB 101 Disease, Clinical Assessment and Lab Testing
TB 101 Disease, Clinical Assessment and Lab Testing Pacific Islands Tuberculosis Controllers Association Conference (PITCA) Clinical Laboratory Breakout None Disclosure Objectives Be able to list and explain
More informationKritische Fragen zum Beitrag der kombinierten PCR für den Nachweis von M. tuberculosis und der Identifizierung von Mutationen auf dem rpob-gen
Kritische Fragen zum Beitrag der kombinierten PCR für den Nachweis von M. tuberculosis und der Identifizierung von Mutationen auf dem rpob-gen Hans L Rieder Union Internationale Contre la Tuberculose et
More informationNational Xpert MTB/RIF Programme
National Xpert MTB/RIF Programme 1. Background to Project This project was initiated at the request of the Honorable Minister of Health, Dr Aaron Motsoaledi, in early 2011, following the World Health Organization
More informationTB/HIV 2 sides of the same coin. Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai
TB/HIV 2 sides of the same coin Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai Global- Tb new cases Diagnosis-Microscopy ZN,Flourescent microscopy(fm) Rapid, inexpensive test Specificity>95%
More informationReceipt within 1 day of specimen collection. Report AFB b smear result within 1 day from receipt of specimen
Recommendation Promote rapid delivery of specimens to the laboratory Use fluorescent acid-fast staining and promptly transmit results by phone, FAX, or electronically Identify growth as acid-fast and use
More informationResearch Methods for TB Diagnostics. Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012
Research Methods for TB Diagnostics Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012 Overview Why do we need good TB diagnostics? What works? What doesn t work? How
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Diagnosis of TB: Laboratory Ken Jost, BA November 12, 2014 Ken Jost, BA has the following disclosures to make: No conflict of interests No relevant
More informationRecognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016
Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the
More informationDiagnosis of drug resistant TB
Diagnosis of drug resistant TB Megan Murray, MD, ScD Harvard School of Public Health Brigham and Women s Hospital Harvard Medical School Broad Institute Global burden of TB 9 million new cases year 2 million
More informationHarmonizing the Use of Molecular & Culture-based DST of Mycobacterium tuberculosis
Harmonizing the Use of Molecular & Culture-based DST of Mycobacterium tuberculosis Grace Lin, MS. Research Scientist grace.lin@cdph.ca.gov APHL 8 th TB Lab Conference San Diego 8-19-13 Harmonizing? There
More informationThe Lancet Infectious Diseases
Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study Susan E Dorman, Samuel G Schumacher, David Alland et al. 2017
More informationNew frontiers: Innovation and Access
8th Regional TB Symposium Tashkent, Uzbekistan Prof. L.N. Chernousova Central Tuberculosis Research Institute (CTRI) Ministry of Health of the Republic of Uzbekistan 28 February 1 March, 2019 1970 1975
More informationCULTURE OR PCR WHAT IS
CULTURE OR PCR WHAT IS BEST FOR AFRICA? Peter R Mason BRTI TB IN AFRICA GLOBAL 9 MILLION NEW CASES/YR 1.5 MILLION TB DEATHS AFRICA 95% TB DEATHS IN LMIC 9/22 HIGH BURDEN COUNTRIES IN AFRICA STRONG LINK
More informationTB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?
Those oral antibiotics are just not working! Inpatient Standards of Care & Discharge Planning S/He s in the Hospital: Now What Do I Do? Dana G. Kissner, MD TB Intensive Workshop, Lansing, MI 2012 Objectives:
More informationMIC = Many Inherent Challenges Sensititre MIC for Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis complex
MIC = Many Inherent Challenges Sensititre MIC for Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis complex Marie Claire Rowlinson, PhD D(ABMM) Florida Bureau of Public Health Laboratories
More informationMDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives. Martie van der Walt TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT
TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives Martie van der Walt IOM Meeting 15-17 January 2013 introduction 1 min 150 words
More informationOriginal Article Evaluation of Xpert MTB/RIF in detection of pulmonary and extrapulmonary tuberculosis cases in China
Int J Clin Exp Pathol 2017;10(4):4847-4851 www.ijcep.com /ISSN:1936-2625/IJCEP0045802 Original Article Evaluation of Xpert MTB/RIF in detection of pulmonary and extrapulmonary tuberculosis cases in China
More informationReport on WHO Policy Statements
Report on WHO Policy Statements Christopher Gilpin TB Diagnostics and Laboratory Strengthening Unit Secretariat, Global Laboratory Initiative Stop TB Department, WHO Geneva New Diagnostics Working Group
More informationPrinciples of laboratory diagnosis of M. tuberculosis. Anne-Marie Demers, MD, FRCPC 11 September 2017
Principles of laboratory diagnosis of M. tuberculosis Anne-Marie Demers, MD, FRCPC 11 September 2017 QUESTION Which statement is false? 1) A smear can only be on a concentrated specimen 2) It is normal
More informationElizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.
The image part with relationship ID rid2 was not found in the file. MDR TB Management Review of the Evolution (or Revolution?) Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist,
More informationDrug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER
Drug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER Outline Drug resistant TB: definitions and epidemiology How does TB become resistant? Current drug susceptibility
More informationINTENSIFIED TB CASE FINDING
INTENSIFIED TB CASE FINDING My friends call me Intensified Case Finding (ICF) I undertake regularly screening all people with, or at high risk of HIV, for symptoms of TB in health care facilities, communities
More informationDiagnosis of Tuberculosis by GeneXpert MTB/RIF Assay Technology: A Short Review
International Journal of Advanced Microbiology and Health Research www.ijamhr.com Volume 1; Issue 1; September 2017; Page No. 20-24 Review Article Diagnosis of Tuberculosis by GeneXpert MTB/RIF Assay Technology:
More information10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose
Disclosures Updates in Tuberculosis I have nothing to disclose Chris Keh, MD Assistant Clinical Professor, Division of Infectious Diseases, UCSF TB Controller, TB Prevention and Control Program, Population
More informationFrances Morgan, PhD October 21, Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS
The Laboratory s Role in Caring for Patients Diagnosed with TB Frances Morgan, PhD October 21, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS EXCELLENCE
More informationMycobacteria Diagnostic Testing in Manitoba. Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline
Mycobacteria Diagnostic Testing in Manitoba Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline Acknowlegements: Assunta Rendina: Charge Tech HSC Lab Joyce Wolf & Dr. Meenu Sharma: NML Dr. Kanchana
More informationDefinitions and reporting framework for tuberculosis 2013 revision. Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013
Definitions and reporting framework for tuberculosis 2013 revision Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013 2-year revision process WHO/HTM/TB/2013.2 2 www.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf
More informationNew Standards for an Old Disease:
New Standards for an Old Disease: Practical Implications of the TB Standards TB Prevention and Control Saskatchewan September 16, 2015 Practical Implications of the TB Standards Learning Objectives At
More informationMinistry of Health. National Tuberculosis Control Program INTEGRATED TB HIV PROGRAM REPORT (JANUARY JUNE 2015)
Ministry of Health National Tuberculosis Control Program INTEGRATED TB HIV PROGRAM REPORT (JANUARY JUNE 2015) Contents Executive summary... 2 Background... 3 National Tuberculosis Program Overview... 3
More informationA retrospective evaluation study of diagnostic accuracy of Xpert MTB/RIF assay, used for detection of Mycobacterium tuberculosis in Greece
Örebro University School of Health and Medical Science Biomedical Laboratory Science Programme 180 credits Degree project in biomedical laboratory science, advanced course, 15 credits May 21, 2015 A retrospective
More informationof clinical laboratory diagnosis in Extra-pulmonary Tuberculosis
New approaches and the importance of clinical laboratory diagnosis in Extra-pulmonary Tuberculosis Bahrmand.AR, Hadizadeh Tasbiti.AR, Saifi.M, Yari.SH, Karimi.A, Fateh.A, Tuberculosis Dept. Pasteur Institute
More informationDiagnosis of tuberculosis in children
Diagnosis of tuberculosis in children H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg Children s Hospital (TCH) Estimated TB incidence
More informationNucleic Acid Amplification Testing for the Diagnosis of TB
Roche Nucleic Acid Amplification Testing for the Diagnosis of TB David Warshauer, PhD Deputy Director, Communicable Diseases Wisconsin State Laboratory of Hygiene 19 th /20 th Century Traditional Algorithm
More informationGeneXpert (Xpert MTB/RIF): what is the future?
GeneXpert (Xpert MTB/RIF): what is the future? Professor Lesley Scott Department of Molecular Medicine and Haematology, University of the Witwatersrand & National Priority Program of the National Health
More informationTOG The Way Forward
TOG 2016- The Way Forward Main Changes in Diagnostic algorithm Definition (Type, Classification, Outcome) Registration at the time of Diagnosis (PHI level Notification Register) Long term follow up (till
More informationUse of the Cepheid GeneXpert to Release Patients from Airborne Isolation
Use of the Cepheid GeneXpert to Release Patients from Airborne Isolation Dave Warshauer, PhD, D(ABMM) Deputy Director, Communicable Diseases Wisconsin State Laboratory of Hygiene WISCONSIN STATE LABORATORY
More informationTB: A Supplement to GP CLINICS
TB: A Supplement to GP CLINICS Chapter 10: Childhood Tuberculosis: Q&A For Primary Care Physicians Author: Madhukar Pai, MD, PhD Author and Series Editor What is Childhood TB and who is at risk? India
More informationEvaluation of Genxpert Real Time PCR POC in the Diagnosis of Multidrug Resistant TB Among Patients Attending NTBLTC Saye-Zaria Nigeria
RESEARCH ARTICLE Open Access Journal of Infectious Diseases and Pathogenesis ISSN 577-7939 Evaluation of Genxpert Real Time PCR POC in the Diagnosis of Multidrug Resistant TB Among Patients Attending NTBLTC
More informationTB Nurse Case Management. March 7-9, Diagnosis of TB: Ken Jost Wednesday March 7, 2012
TB Nurse Case Management San Antonio, Texas March 7-9, 2012 Diagnosis of TB: Laboratory Ken Jost Wednesday March 7, 2012 Ken Jost has the following disclosures to make: No conflict of interests No relevant
More informationProgress Report July 2014
Progress Report July 2014 Table of Contents Background to project 3 Assays performed to date 5 Rif Concordance 8 Errors 8 Monthly uptake since implementation started 10 Specific GeneXpert Site Progress
More informationClinical and Public Health Impact of Nucleic Acid Amplification Tests (NAATs) for Tuberculosis
Clinical and Public Health Impact of Nucleic Acid Amplification Tests (NAATs) for Tuberculosis Amit S. Chitnis, MD, MPH; Pennan M. Barry, MD, MPH; Jennifer M. Flood, MD, MPH. California Tuberculosis Controllers
More informationAssessing the programmatic management of drug-resistant TB
Assessing the programmatic management of drug-resistant TB a. Review the programmatic management of drug-resistant TB patients with the TB manager. i. What is the size of MDR-TB problem locally? How many
More informationLatent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016
Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Randy Culpepper, MD, MPH Deputy Heath Officer/Medical Director Frederick County Health Department March 16, 2016 2 No
More informationXpert MTB/RIF assay validation experience --- impact and plan in China
Xpert MTB/RIF assay validation experience --- impact and plan in China Dr. Zhao Yanlin Chinese Center for Disease Control & Prevention Dr. Richard O Brien FIND April. 16, 2013 Progress Contribution for
More informationLaboratory Diagnosis and Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis Complex. Objectives
Laboratory Diagnosis and Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis Complex Marie-Claire Rowlinson, PhD D(ABMM) Calin Chiribau, PhD, MT(ASCP) Florida Bureau of Public Health Laboratories
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Churchyard GJ, Stevens WS, Mametja LD, et al.
More information7. Are you currently engaged in research that could support new TB diagnostic assay development? Yes No
Determining Future TB Reference Material Requirements WHO/TDR TB Expert & End-User Survey Properly handled samples from well-characterized patients with suspected tuberculosis from disease endemic countries
More informationIdentify, Evaluate, and Treat! Steps to Improve TB Contact Investigation in the Pacific November 27 30, 2018
TB Laboratory Training Chuuk, FedSM Vasiti Uluiviti Regional Lab Strengthening Coordinator PIHOA November 29 th 218 1 Learning objectives Provide an overview of TB lab activities in the USAPI Demonstration
More informationRevised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor
Revised National Tuberculosis Control Programme (RNTCP) Dr.Kishore Yadav J Assistant Professor Global scenario*: Burden of TB Incidence : 9.6 million (58% SEAR and Western Pacific) Deaths : 1.5 million
More informationAutomated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance:
Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary
More informationTB FIT Modelling. 24th Annual PhilCAT Convention. Ivor Langley and Ewan Tomeny Liverpool School of Tropical Medicine AUGUST 2017
TB FIT Modelling 24th Annual PhilCAT Convention Ivor Langley and Ewan Tomeny Liverpool School of Tropical Medicine AUGUST 2017 TB-FIT - Objectives 1. Develop a computer model of patient pathways for diagnosis
More informationTB is Local. Barry Chin, Boston Globe, 10/15/2008. * BUT only in appropriate setting
Diagnosis of Tuberculosis 2012 New Tools, Tricks, Thinking? John Bernardo, M.D. Pulmonary Section, Boston University School of Medicine Massachusetts Department of Public Health Objectives To review the
More informationSA TB Guidelines The interface with Advanced Clinical Care
SA TB Guidelines The interface with Advanced Clinical Care Dr Kogie Naidoo (MBCHB, PHD) Head: CAPRISA Treatment Research Programme Honorary Lecturer - UKZN Department of Public Heath Medicine Annual Workshop
More informationChallenges in Capacity in SA for diagnosing DR-TB
National Tuberculosis Reference Laboratory Challenges in Capacity in SA for diagnosing DR-TB March 2010 Gerrit Coetzee Rapid response to XDR-TB WHO Global Task Force on XDR-TB, October 2006 Accelerate
More informationOnline Annexes (2-4)
Online Annexes (2-4) to WHO Policy update: The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin THE END TB STRATEGY Online Annexes (2-4) to WHO Policy update:
More informationDiagnosis of HIV-Associated Tuberculosis
Diagnosis of HIV-Associated Tuberculosis Stephen D. Lawn Desmond Tutu HIV Centre Institute of Infectious Disease and Molecular Medicine University of Cape Town Dept. Of Clinical Research, Faculty of Infectious
More informationPlanning for the implementation of new diagnostic tests
Planning for the implementation of new diagnostic tests Dr Christopher Gilpin Laboratories, Diagnostics & Drug Resistance WHO Global TB Programme, Geneva GLOBAL TB PROGRAMME Workshop on the development
More informationPCR and direct amplification for tuberculosis diagnosis. Emmanuelle CAMBAU University Paris Diderot, APHP, Saint Louis-Lariboisière Hospital,
PCR and direct amplification for tuberculosis diagnosis Emmanuelle CAMBAU University Paris Diderot, APHP, Saint Louis-Lariboisière Hospital, Paris, France Educational Workshop 05- ECCMID 2015 Copenhagen
More informationObjectives. TB Laboratory Methods
TB Laboratory Methods Beverly Metchock, Dr.P.H., D(ABMM) Team Leader, Reference Laboratory, Mycobacteriology Laboratory Branch February 2011 Objectives General overview of mycobacteriology (TB) lab practices
More information2018 Tuberculosis Clinical Intensive: Infection Prevention & Control. > No disclosures
2018 Tuberculosis Clinical Intensive: Infection Prevention & Control > No disclosures 1 Objectives By the end of today s session, hopefully you will be able to: > Recognize potential TB exposures in healthcare
More informationReport of TB/HIV Diagnostics Task Force. Barbara Laughon NIAID, NIH
Report of TB/HIV Diagnostics Task Force Barbara Laughon NIAID, NIH TB/HIV Diagnostics Task Force STOP TB WG on New Diagnostics reorganized with liaisons from other WG A statement of needs requested from
More informationTowards Harmonization of Mycobacteriology in TB Trials. Study 31/ACTG 5349 Key Elements of Mycobacteriology Laboratory Procedures
Study 31/ACTG 5349 Key Elements of Mycobacteriology Laboratory Procedures: Towards Harmonization of Mycobacteriology in TB Trials Title Author(s) Study 31/ACTG 5349 Key Elements of Mycobacteriology Laboratory
More informationWELCOME. Lab Talk: What a Nurse Hears. April 18, NTNC Annual Meeting Lab Talk: What a Nurse Hears
Lab Talk: What a Lab Talk: What a Max Salfinger, MD, FIDSA, FAAM Executive Director, Advanced Diagnostic Laboratories Laboratory Director, Mycobacteriology & Pharmacokinetics National Jewish Health Lisa
More informationRole of Xpert MTB/RIF Assay in the Diagnosis of Pulmonary Tuberculosis and Rifampicin Resistance
Role of Xpert MTB/RIF Assay in the Diagnosis of Pulmonary Tuberculosis and Rifampicin Resistance Taher Abdel -Aziz 1, Naglaa Azab 2, Eman AboElabass 3 & I.M El-deen 4 1 Ph.D of Biochemistry, Faculty of
More informationTB infection control: overview and importance
TB infection control: overview and importance John Ferguson, Newcastle, NSW Infectious Diseases & Microbiology jferguson@hnehealth.nsw.gov.au Goroka Hospital, September 2014 Patterns of TB disease Latent
More informationLaboratory Diagnostic Techniques. Hugo Donaldson Consultant Microbiologist Imperial College Healthcare NHS Trust
Laboratory Diagnostic Techniques Hugo Donaldson Consultant Microbiologist Imperial College Healthcare NHS Trust Learning Objectives 1) When to consider a diagnosis of TB 2) When to consider a referral
More informationGeneral Session IV - Dale Schwab April 20, 2017
The Culture of Clinical Commercial Labs Presented by: Dale Schwab PhD, Senior Scientific Director, Infectious Disease April 20, 2017 Objectives Challenges for the reference laboratory in MTB diagnosis/opportunities
More informationVirtual Implementation Evaluation of Tuberculosis diagnostics in Tanzania Ivor Langley, Liverpool School of Tropical Medicine
Virtual Implementation Evaluation of Tuberculosis diagnostics in Tanzania Ivor Langley, Liverpool School of Tropical Medicine 3rd sector OR and developing countries 27th March 2013, London School of Economics
More informationXpert MTB/Rif What place for TB diagnosis in MSF projects? Francis Varaine, MSF Geneva, 29/11/10
Xpert MTB/Rif What place for TB diagnosis in MSF projects? Francis Varaine, MSF Geneva, 29/11/10 Introduction Excellent performances, rapid results, and easy to use Questions Where and how are we going
More informationPrimary Care and TB Control Dr Helen Booth Consultant Thoracic Physician, UCLH Clinical Lead, Integrated TB NCL-Service
Primary Care and TB Control Dr Helen Booth Consultant Thoracic Physician, UCLH Clinical Lead, Integrated TB NCL-Service North Central London TB Service TBService@nhs.net After Action Review Could we have
More informationMolecular assays in Tuberculosis. Jatin Yegurla Junior resident
Molecular assays in Tuberculosis Jatin Yegurla Junior resident 17-3-2018 Contents Introduction TB-PCR Line Probe assay (LPA) GenoType MTBDRsl test (Second line LPA) Xpert MTB/RIF (GeneXpert) (CB-NAAT)
More informationMEMORANDUM. Re: Guidance for follow-up of newly-arrived individual with Class B1 Tuberculosis Pulmonary Tuberculosis, no treatment
MEMORANDUM To: From: Local Board of Health John Bernardo, MD, Tuberculosis Medical Officer Jennifer Cochran, MPH, Division Director Division of Global Populations and Infectious Disease Prevention Bureau
More informationUpdate on Management of
Update on Management of DR TB Definitions Presumptive MDR-TB A patient suspected of drug-resistant TB, based on RNTCP criteria for submission of specimens for drug-susceptibility testing MDR-TB Case A
More informationMolecular Methods in the Diagnosis of Drug Resistant Tuberculosis. Dr Sahajal Dhooria
Molecular Methods in the Diagnosis of Drug Resistant Tuberculosis Dr Sahajal Dhooria What is drug resistant TB? Definitions MDR TB defined as resistance to isoniazid and rifampicin, with or without resistance
More informationRapid Diagnosis and Detection of Drug Resistance in Tuberculosis
Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis YAM Wing-Cheong 任永昌 Department of Microbiology The University of Hong Kong Tuberculosis Re-emerging problem in industrialized countries
More informationRevised National Tuberculosis Control Programme
Revised National Tuberculosis Control Programme 1 OUTLINE OF PRESENTATION Introduction Burden Of The Disease Evolution Of RNTCP Goals And Objectives Of RNTCP DOTS Stop TB Strategy Organization RNTCP Endorsed
More informationDetection of Multidrug Resistance and Characterization of Mutations in Mycobacterium tuberculosis Isolates in Raichur District, India
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 10 (2017) pp. 1543-1549 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.610.185
More informationHeather Alexander, PhD
Xpert MTB/RIF: An Opportunity to Strengthen Laboratory Systems and Bridge the Laboratory-Program Gap Heather Alexander, PhD International Laboratory Branch Division of Global HIV/AIDS Centers for Disease
More informationNucleic Acid Amplification Test for Tuberculosis. Heidi Behm, RN, MPH Acting TB Controller HIV/STD/TB Program Oregon, Department of Health Services
Nucleic Acid Amplification Test for Tuberculosis Heidi Behm, RN, MPH Acting TB Controller HIV/STD/TB Program Oregon, Department of Health Services What is this test? Nucleic Acid Amplification Test (NAAT)
More informationIntroduction. Diagnosis of extrapulmonaryand paediatric tuberculosis. Extrapulmonary tuberculosis EPTB SASCM WORKSHOP 2014/05/24
Diagnosis of extrapulmonaryand paediatric tuberculosis AW Dreyer Centre for Tuberculosis NICD Introduction Part of the global efforts to control tuberculosis (TB) include improving case detection, especially
More informationManagement of Tuberculosis Training for Health Facility Staff SECOND EDITION. B. Detect Cases of TB
Management of Tuberculosis Training for Health Facility Staff SECOND EDITION B. Detect Cases of TB Management of Tuberculosis Training for Health Facility Staff Second Edition B DETECT CASES OF TB WHO
More information